Last update Oct. 20, 2023
Incompatible
We do not have alternatives for Dihydroergocryptyne Mesilate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dihydroergocryptyne Mesilate in other languages or writings:
Dihydroergocryptyne Mesilate belongs to this group or family:
Main tradenames from several countries containing Dihydroergocryptyne Mesilate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | baja-los | % |
Molecular weight | 674 | daltons |
Tmax | 3 | hours |
T½ | 25 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dihydroergocryptine mesylate is a derivative of ergot, a component of codergocrine mesylate, and has similar actions. It has been used in the treatment of migraine, parkinsonism, senile dementia, cerebrovascular and peripheral vascular disorders, prolactinomas and to inhibit lactation. Oral administration.
At the time of the last update, we found no published data on its excretion in breast milk.
Like all ergot derivatives, it is a dopaminergic agonist and therefore reduces prolactin secretion and may suppress lactation. (Mirkou 2012, Nappi 1993)
See below the information of these related products: